A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

NCT06474663 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants

Conditions

Refractory Acute Leukemia
Relapsed Acute Leukemia

Interventions

DRUG: Cladribine
DRUG: Cytarabine
DRUG: Sorafenib
DRUG: Decitabine

Sponsor

M.D. Anderson Cancer Center